🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT03327428
Recruiting Observational

Sickle-cell Disease Registry of the GPOH

NCT03327428 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2016-12-15
Last updated
2025-01-24

Condition(s) studied

Sickle Cell Disease

Study summary

Sickle cell disease is one of the most common hereditary diseases. Most severe complications can be avoided if the disease is detected early and treated appropriately.

The sickle cell disease registry of the Society for Paediatric Oncology/Haematology aims at describing the epidemiology of sickle cell disease in German-speaking central Europe. Patients with sickle cell disease will be characterized clinically and genetically and treatment will be documented with the aim to find predictors of the course of disease.

In addition, the registry results should provide a solid evidence base to incorporate sickle cell disease into routine newborn screening and to update the national guidelines for the management of patients suffering from sickle cell disease in Germany.

A consortium of five university hospitals (Berlin, Frankfurt, Hamburg, Heidelberg, Ulm) has been mandated by the Society for Paediatric Oncology/Haematology to implement this registry.

The number of participating centers is constantly increasing and new centers that take care of either pediatric or adult patients with sickle cell disease are encouraged to support the registry.

For further information please refer to: http://www.sichelzellkrankheit.info/

Eligibility

Sex
ALL
Min age
0 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * signed informed consent * current residency in either Germany, Austria or Switzerland * sickle cell disease confirmed by hemoglobin analysis or molecular genetic analysis * Homozygous sickle cell disease (HbSS) * HbSC disease * Sickle cell disease HbS / bThal * Other, rare sickle cell syndromes such as HbS/OArab, HbS/HPFH, HbS/E, HbS/D Punjab, HbS/C Harlem, HbC/S Antilles, HbS/Quebec-CHORI, HbA/S Oman, HbA/Jamaica Plain Exclusion Criteria: \- isolated heterozygous trait for HbS

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Center for Child and Adolescent Medicine, University Medical Center Heidelberg Heidelberg Baden-Wurttemberg Recruiting

More University Hospital Heidelberg trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03327428 on ClinicalTrials.gov ↗ ← All trials in Germany